Bristol Myers Squibb announces topline Results from Phase 3 Independence trial for Reblozyl
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
This achievement underscores our unwavering commitment to upholding the highest standards of quality, safety, and regulatory compliance
Vimta Labs has reported total income of Rs. 99.31 crores during the period ended June 30, 2025
Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough
The company is addressing these observations comprehensively
The receipt of EIR reaffirms the company's commitment to maintaining global quality standards
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
Subscribe To Our Newsletter & Stay Updated